Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Bart J. F. van den Bemt
ResearcherPublications, citations & collaboration network
Bart J. F. van den Bemt is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 306 works, 6,051 citations, an h-index of 42 and an i10-index of 134.
306
Works
6,051
Citations
42
h-index
134
i10-index
How has Bart J. F. van den Bemt's publication output changed over time?
ScholarIQpublication output · 2009–2022
Output grew0% over the shown period — from 1 works in 2009 to 1 in 2022.
1
1
3
1
1
2
1
1
20092012201520172018201920212022
What are the most-cited papers on Bart J. F. van den Bemt?
ScholarIQmost cited works
Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature
Bart J. F. van den Bemt, Hanneke Zwikker, Cornelia HM van den Ende
Expert Review of Clinical Immunology. 2012321 CitationsOPEN ACCESS
Prevalence and Preventability of Drug‐Related Hospital Readmissions: A Systematic Review
Najla El Morabet, Elien B. Uitvlugt, Bart J. F. van den Bemt, Patricia M. L. A. van den Bemt, Marjo J. A. Janssen, Fatma Karapinar‐Çarkit
Journal of the American Geriatrics Society. 2018241 Citations
Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
Noortje van Herwaarden, Aatke van der Maas, M.J.M. Minten, F.H.J. van den Hoogen, Wietske Kievit, Ronald van Vollenhoven, J. W. J. Bijlsma, Bart J. F. van den Bemt, Alfons A den Broeder
BMJ. 2015182 CitationsOPEN ACCESS
Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab
Lieke Tweehuysen, Bart J. F. van den Bemt, Iris L. van Ingen, Alphons J.L. de Jong, W.H. van der Laan, F.H.J. van den Hoogen, Alfons A den Broeder
Arthritis & Rheumatology. 2017164 Citations
Adherence Rates and Associations with Nonadherence in Patients with Rheumatoid Arthritis Using Disease Modifying Antirheumatic Drugs
Bart J. F. van den Bemt, F.H.J. van den Hoogen, B. Benraad, Yechiel A. Hekster, Piet L. C. M. van Riel, Wim van Lankveld
The Journal of Rheumatology. 2009142 CitationsOPEN ACCESS
Related on ScholarIQ
Radboud University Nijmegen
Institution
Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature
Paper
Prevalence and Preventability of Drug‐Related Hospital Readmissions: A Systematic Review
Paper
Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
Paper
Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab
Paper
Adherence Rates and Associations with Nonadherence in Patients with Rheumatoid Arthritis Using Disease Modifying Antirheumatic Drugs
Paper